| Literature DB >> 36060944 |
Darja Lavogina1,2, Nadja Visser3, Külli Samuel2, Eva Davey3, Richelle D Björvang4, Jasmin Hassan4, Jani Koponen5, Panu Rantakokko5, Hannu Kiviranta5, Ago Rinken1, Matts Olovsson3, Andres Salumets2,4,6, Pauliina Damdimopoulou4.
Abstract
Multiple studies have shown associations between exposure to endocrine disrupting chemicals (EDCs) and reduced fertility in women. However, little is known about the target organs of chemical disruption of female fertility. Here, we focus on the hormone-sensitive uterine lining, the endometrium, as a potential target. Decidualization is the morphological and functional change that endometrial stromal cells undergo to support endometrial receptivity, which is crucial for successful implantation, placentation, and pregnancy. We investigated the effect of nine selected EDCs on primary human endometrial stromal cell decidualization in vitro. The cells were exposed to a decidualization-inducing mixture in the presence or absence of 1 μM of nine different EDCs for nine days. Extent of decidualization was assessed by measuring the activity of cAMP dependent protein kinase, Rho-associated coiled-coil containing protein kinase, and protein kinase B in lysates using photoluminescent probes, and secretion of prolactin into the media by using ELISA. Decidualization-inducing mixture upregulated activity of protein kinases and prolactin secretion in cells derived from all women. Of the tested chemicals, dichlorodiphenyldichloroethylene (p,p'-DDE), hexachlorobenzene (HCB) and perfluorooctanesulfonic acid (PFOS) significantly reduced decidualization as judged by the kinase markers and prolactin secretion. In addition, bisphenol A (BPA) reduced prolactin secretion but did not significantly affect activity of the kinases. None of the EDCs was cytotoxic, based on the assessment of total protein content or activity of the viability marker casein kinase 2 in lysates. These results indicate that EDCs commonly present in the blood circulation of reproductive-aged women can reduce decidualization of human endometrial stromal cells in vitro. Future studies should focus on detailed hazard assessment to define possible risks of EDC exposure to endometrial dysfunction and implantation failure in women.Entities:
Keywords: decidualization; endocrine disrupting chemical; human endometrium; infertility; per- and polyfluorinated alkyl substances (PFASs); persistent organic pollutants (POPs); phthalate; primary stromal cells
Mesh:
Substances:
Year: 2022 PMID: 36060944 PMCID: PMC9437351 DOI: 10.3389/fendo.2022.903505
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Summary of literature on the effects of EDCs on human endometrial stromal cell decidualization in vitro.
| Origin of cells | EDC exposure (concentrations, time) | Decidualization protocol | Key results | Reference |
|---|---|---|---|---|
| Endometrial biopsies from gynecological surgery, proliferative state (n=8) | BPA and TCL | 10 µM P4 for 10 days | TCL and BPA 100 nM and 100 pM arrested cell cycle. | ( |
| First trimester (6–8 weeks) decidual tissue from induced abortion (n=3-5) | PFOS first range from 0.0001 to 1 μM, then 0.01 μM was used 24 h or 48 h | 0.5 mM 8-Br-cAMP and 1 µM MPA for 24 h or 48 h | PFOS decreased decidualization markers in a concentration-dependent-way. | ( |
| Telomerase-immortalized human endometrial stromal cells (THESC, ATCC CRL-4003) (n=3) | OP and NP 5, 10, 15, 20, 25, or 30 μM. Then 5 μM and 10 μM OP, and 5 μM NP were used 12 days | 0.5 mM db-cAMP and 1 µM MPA for 12 days | OP (from 20 µM) and NP (from 15 µM) reduced cell viability, but not for lower concentrations. | ( |
| Endometrial biopsies from women receiving infertility treatments (n=15) | 1 nM to 10 μM BPA, BPF, and BPS | 0.5 mM 8-Br-cAMP, 10 nM E2 and 1 μM P4 for 9 days | No effect on PRL and IGFBP-1 expression. | ( |
| Endometrial biopsies from hysterectomies early state cervical cancer, proliferative state and HESC (cell line) | BPA 10 pM, 100 pM, 1 nM, 10 nM, 100 nM, 1 μM, 10 μM. 10 μM to study ER | 1 μM MPA, and 0.5 mM cAMP for 6 days | Morphological change impaired by 10 nM and 10 μM BPA. | ( |
| Endometrial biopsies from hysterectomy, benign reason (n=8) | BPA 5, 25, 50 and 100 μM 48 h | 0.5 mM 8-Br-cAMP 96 h | 5 μM and 100 μM BPA decreased proliferation. | ( |
| Endometrial biopsies from hysterectomy or hysteroscopy, proliferative state (n=6) | BPA (1 pM - 1 µM) | 3 days E2 100 nM, then E2+P4 100 nM and 10 µM for 12 days | No effect on proliferation. | ( |
| Decidua parietalis of the placental membrane (n=4) | BPA 1 ng/mL to 20 µg/mL | E2 36 nM, MPA 1 μM and db-cAMP 0.5 mM for 8 days | 20 µg reduces | ( |
| Endometrial biopsies from patients receiving IVF treatment (n=4) | Mancozeb 3 μg/mL | 0.5 mM cAMP, 10 nM 17β-E2 and 1 μM P4 for 9 days | No effect on | ( |
BPA, Bisphenol A; BPF, Bisphenol F; BPS, Bisphenol S; cAMP, Cyclic adenosine monophosphate; CCND2, Cyclin D2; E2, Estrogen; ER/ESR1, Estrogen receptor alpha; EZH2, Enhancer of Zeste Homolog 2; FOXO1, Forkhead Box Protein O1; HOXA10, Homeobox A10; IGFBP-1/IGFBP1, Insulin-like Growth Factor Binding Protein 1; IVF, In Vitro Fertilisation; LEFTY2, Left-Right Determination Factor 2; LIF, Leukemia Inhibitor Factor; MIF, Macrophage Migration Inhibitory Factor; MLL1, Mixed-Lineage Leukemia 1; MPA, Medroxyprogesterone acetate; NP, Nonylphenol; OP, Octylphenol; P4, Progesterone; PFOS, Perfluorooctane sulfonic acid; PGR, Progesterone Receptor; PRL/PRL, prolactin; TCL, Triclosan.
Characteristics of tissue donors.
| Donor | Age | Fertility | Indication | BMI (kg/m2) | Hormone treatment | Smoker | Gravidity | Parity |
|---|---|---|---|---|---|---|---|---|
| eSC4 | 28 | unknown | Pelvic pain, especially during menstruation | 18 | No | No | 0 | 0 |
| eSC5 | 41 | yes | Pelvic pain, especially around and at menstruation | 24 | No | No | 4 | 3 |
| eSC8 | 26 | yes | Pelvic pain, especially around and at menstruation | 26 | No | No | 2 | 2 |
| eSC12 | 41 | yes | Menorrhagia and menstrual pain | 29 | No | No | 4 | 1 |
Figure 1Experimental setup. (A) Workflow of the decidualization disruption assay. Human endometrial tissue samples were digested to single-cell suspension and endometrial stromal cells (eSCs) were isolated. The eSCs were cultured for two passages before they were cryopreserved for later use in experiments. To induce decidualization, the cells were exposed to decidualization mixture (DC-mix) composed of estradiol (E2), progesterone (P4), 8-Br-cAMP and IBMX for nine days. To test the effect of EDCs on decidualization, the cells were co-exposed to DC-mix and 1 μM of EDCs. Decidualization was assessed by measuring prolactin (PRL) secretion in culture media and activation of protein kinases PKA, ROCK and Akt in lysates of treated cells. Effects on cell proliferation and viability were estimated by the total protein concentration and activity of the viability marker CK2 in lysates of treated cells. (B) Initial screening was performed with nine EDCs on eSCs from two different women. From these nine chemicals, four were chosen for the exposure studies with ESCs from two additional women. (C) The principle of the protein kinase activity assay in lysates. Binding of a generic kinase probe to the mixture of target kinases present in lysate samples produces long-lifetime photoluminescent signal. Activity of each protein kinase of interest is subsequently established by displacing the probe with a competing selective inhibitor (H89 in case of PKA, Y-27632 in case of ROCK, GSK-690693 in case of Akt, and CX-4945 in case of CK2).
Figure 2Screening of nine EDCs for effects on decidualization. The eSCs of two women (N=2) were exposed to the decidualization-inducing mixture (DC-mix) in the absence or presence of 9 different EDCs (1 µM) for 9 days, and 10 nM E2 was used as a negative control. Altogether 10 independent assays were carried out (n=10). Protein kinase activity was assessed in lysates (normalized to protein content) using a competitive photoluminescent probe displacement assay, and calculated as percentage of DC-mix (100%) for (A) PKAc, (B) ROCK and (C) Akt/PKB. (D) Secreted PRL was measured in spent media representing the last 72 h of the in vitro treatment using a human PRL ELISA kit. Values are expressed as mean percentage of DC-mix alone ± SEM (N = 2, n = 10). Significance is calculated by one-way ANOVA with Dunnett test for multiple comparisons (95% CI) relative to DC-mix and indicated as *P<0.05, **P<0.01 and ***P<0.001 and ns, not significant. The dotted line corresponds to 100%.
Figure 3Effect of EDCs (1 μM) and selective control inhibitors (1 μM) on activities of recombinant protein kinases to assess whether EDCs have a direct effect on the protein kinases. Recombinant protein kinases (A) full-length PKAcα; (B) His6-ROCK2 (amino acids 11-552); (C) His6-Akt3 (S472D mutant, amino acids 117-end); (D) CK2α (amino acids 1-335) were used. The graph shows the averaged data of the three measurements as mean ± SEM (n = 2 for each kinase, performed in duplicates). Significance is calculated by one-way ANOVA with Dunnett test for multiple comparisons (95% CI) relative to no inhibitor and indicated as *P<0.05; **P<0.01 ***P<0.001 and ns, not significant. The dotted line corresponds to 100%.
Figure 4Effect of DDE, HCB, BPA and PFOS on decidualization and viability markers. The eSCs of two additional women were exposed to the decidualization-inducing mixture (DC-mix) in the absence or presence of 1 µM DDE, HCB, BPA, PFOS for 9 days. The effects of EDCs were compared to the positive control DC-mix, and 10 nM E2 was used as negative control. Total protein concentration for different treatments was normalized after lysis of the eSCs. Protein kinase activity for (A) PKAc, (B) ROCK2 and (C) Akt/PKB was assessed in lysates using a competitive photoluminescent probe displacement assay and calculated as percentage of DC-mix (100%). (D) Secreted PRL was measured in media aliquots (collected following the last 72 h of the in vitro treatment) using a human PRL ELISA kit. The impact of the exposures on viability of the endometrial stromal cells in culture during decidualization assays was assessed by the activity of the viability marker kinase CK2 in lysates (E) as well as evaluating the total protein concentrations in lysates at the end of the assay (F). Values are expressed as mean percentage of DC-mix alone ± SEM based on cells derived from 4 women (N=4) tested in 4 to 6 independent experiments (n=4-6). Significance is calculated by one-way ANOVA with Dunnett test for multiple comparisons (95% CI) relative to DC-mix and indicated as *P<0.05, **P<0.01 and ***P<0.001 and ns, not significant. The dotted line corresponds to 100%.
Figure 5Summary of the 1 μM EDC impact on decidualization markers following in vitro treatment of ESCs. The radar plot depicts a characteristic ‘fingerprint’ of various decidualization- and viability-related markers measured in this study and the alterations caused by the presence of EDCs (as seen by shift of pattern related to that of the DC-mix). The y-axis shows normalized activities (%) of PKA, ROCK and Akt, normalized secretion (%) of prolactin (PRL), normalized reciprocal of CK2 activity (%) and normalized reciprocal of total protein content (indicated as Bradford) (%). In each case, 100% corresponds to the value measured for the decidualization mixture; the reciprocal values for CK2 activity and total protein content reflect the fact that these markers are reduced during decidualization. The graph summarizes data from all independent experiments performed within the study (N = 4 and n = 21 for each EDC); for better clarity, error bars are not shown.